[{"orgOrder":0,"company":"Westat","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute on Drug Abuse | National Institute of Mental Health | National Institutes of Health | Florida State University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"||Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Westat \/ Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute on Drug Abuse | National Institute of Mental Health | National Institutes of Health | Florida State University","highestDevelopmentStatusID":"11","companyTruncated":"Westat \/ Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute on Drug Abuse | National Institute of Mental Health | National Institutes of Health | Florida State University"},{"orgOrder":0,"company":"Westat","sponsor":"VITRAC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VIC-1911","moa":"||Aurora kinase A (AURKA)","graph1":"Oncology","graph2":"Phase I","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Westat \/ Westat","highestDevelopmentStatusID":"6","companyTruncated":"Westat \/ Westat"},{"orgOrder":0,"company":"Westat","sponsor":"US Department of Defense | Clinipace Worldwide","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"||Succinate semialdehyde dehydrogenase","graph1":"Nephrology","graph2":"Phase II","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Westat \/ US Department of Defense | Clinipace Worldwide","highestDevelopmentStatusID":"8","companyTruncated":"Westat \/ US Department of Defense | Clinipace Worldwide"},{"orgOrder":0,"company":"Westat","sponsor":"US Department of Defense | Clinipace Worldwide","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"||Succinate semialdehyde dehydrogenase","graph1":"Nephrology","graph2":"Phase II","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Westat \/ US Department of Defense | Clinipace Worldwide","highestDevelopmentStatusID":"8","companyTruncated":"Westat \/ US Department of Defense | Clinipace Worldwide"}]

Find Clinical Drug Pipeline Developments & Deals by Westat

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Doxycycline Hyclate,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase IV

                          Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute on Drug Abuse | National Institute of Mental Health | National Institutes of Health | Florida State University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 17, 2024

                          Lead Product(s) : Doxycycline Hyclate,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute on Drug Abuse | National Institute of Mental Health | National Institutes of Health | Florida State University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 16, 2022

                          Lead Product(s) : VIC-1911,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : VITRAC Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 28, 2020

                          Lead Product(s) : Divalproex Sodium,Inapplicable

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : US Department of Defense | Clinipace Worldwide

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 28, 2020

                          Lead Product(s) : Divalproex Sodium,Inapplicable

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : US Department of Defense | Clinipace Worldwide

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          July 22, 2019

                          Lead Product(s) : TMB-365,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Recipient : TaiMed Biologics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 12, 2019

                          Lead Product(s) : Ibalizumab,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : TaiMed Biologics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 23, 2016

                          Lead Product(s) : PPV-23,PCV-10

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Gansu Provincial Maternal and Child Health Care Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 14, 2016

                          Lead Product(s) : Ibalizumab,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : TaiMed Biologics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Ferrous Gluconate,Inapplicable

                          Therapeutic Area : Hematology

                          Study Phase : Undisclosed

                          Sponsor : Versiti | American National Red Cross | The Institute for Transfusion Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          September 19, 2014

                          Lead Product(s) : Ferrous Gluconate,Inapplicable

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Versiti | American National Red Cross | The Institute for Transfusion Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Lamivudine,Zidovudine,Efavirenz,Raltegravir Potassium

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase IV

                          Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 13, 2012

                          Lead Product(s) : Lamivudine,Zidovudine,Efavirenz,Raltegravir Potassium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank